(LRCX) Lam Research - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US5128073062
Stock: Deposition, Etch, Clean, Refurbish, Service
Total Rating 89
Risk 99
Buy Signal 0.59
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.90% |
| Yield on Cost 5y | 1.94% |
| Yield CAGR 5y | -35.32% |
| Payout Consistency | 100.0% |
| Payout Ratio | 16.9% |
| Risk 5d forecast | |
|---|---|
| Volatility | 65.4% |
| Relative Tail Risk | -4.77% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 2.18 |
| Alpha | 157.82 |
| Character TTM | |
|---|---|
| Beta | 1.957 |
| Beta Downside | 1.805 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.10% |
| CAGR/Max DD | 1.46 |
Description: LRCX Lam Research January 26, 2026
Lam Research Corp (NASDAQ:LRCX) designs, manufactures, markets, refurbishes, and services a broad portfolio of semiconductor processing equipment used across the integrated-circuit value chain worldwide. Its product families span deposition (ALTUS, SABRE, SPEED, Striker, VECTOR), etch (Flex, Vantex, Kiyo, Syndion, Versys), cleaning (Coronus, Da Vinci, DV-Prime, EOS, SP series) and integrated platforms (Reliant, Sense.i), supported by aftermarket services and upgrades.
In its most recent fiscal year (FY 2025), Lam reported revenue of $15.2 billion, a 12 % year-over-year increase driven by higher demand for advanced-node equipment and a 23 % operating margin, reflecting disciplined cost control. Capital expenditures rose to $2.1 billion, underscoring continued investment in next-generation atomic-layer-deposition and high-density plasma technologies. The company’s exposure to the China market remains a material risk, as Chinese fab capacity growth slowed to 3 % YoY in Q3 2025 amid policy constraints, while global fab-as-a-service (FAAS) capacity is expanding at roughly 8 % annually, supporting long-term demand for Lam’s equipment.
For a deeper, data-driven assessment of Lam’s valuation dynamics, you may find ValueRay’s analytical tools useful.
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income: 6.21b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.31 > 0.02 and ΔFCF/TA 9.20 > 1.0 |
| NWC/Revenue: 37.96% < 20% (prev 50.97%; Δ -13.01% < -1%) |
| CFO/TA 0.33 > 3% & CFO 7.12b > Net Income 6.21b |
| Net Debt (-1.70b) to EBITDA (7.50b): -0.23 < 3 |
| Current Ratio: 2.26 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.27b) vs 12m ago -2.01% < -2% |
| Gross Margin: 49.80% > 18% (prev 0.48%; Δ 4933 % > 0.5%) |
| Asset Turnover: 99.73% > 50% (prev 81.70%; Δ 18.03% > 0%) |
| Interest Coverage Ratio: 41.06 > 6 (EBITDA TTM 7.50b / Interest Expense TTM 172.9m) |
Altman Z'' 10.00
| A: 0.36 (Total Current Assets 14.02b - Total Current Liabilities 6.21b) / Total Assets 21.39b |
| B: 1.47 (Retained Earnings 31.50b / Total Assets 21.39b) |
| C: 0.34 (EBIT TTM 7.10b / Avg Total Assets 20.62b) |
| D: 2.79 (Book Value of Equity 31.40b / Total Liabilities 11.25b) |
| Altman-Z'' Score: 12.44 = AAA |
Beneish M -2.99
| DSRI: 0.83 (Receivables 3.49b/3.30b, Revenue 20.56b/16.21b) |
| GMI: 0.96 (GM 49.80% / 47.60%) |
| AQI: 1.10 (AQ_t 0.22 / AQ_t-1 0.20) |
| SGI: 1.27 (Revenue 20.56b / 16.21b) |
| TATA: -0.04 (NI 6.21b - CFO 7.12b) / TA 21.39b) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of LRCX shares?
As of February 07, 2026, the stock is trading at USD 231.01 with a total of 13,845,224 shares traded.
Over the past week, the price has changed by -1.05%, over one month by +11.62%, over three months by +42.67% and over the past year by +181.45%.
Over the past week, the price has changed by -1.05%, over one month by +11.62%, over three months by +42.67% and over the past year by +181.45%.
Is LRCX a buy, sell or hold?
Lam Research has received a consensus analysts rating of 4.33.
Therefore, it is recommended to buy LRCX.
- StrongBuy: 20
- Buy: 4
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the LRCX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 257.1 | 11.3% |
| Analysts Target Price | 257.1 | 11.3% |
| ValueRay Target Price | 351.2 | 52% |
LRCX Fundamental Data Overview January 31, 2026
P/E Trailing = 51.0576
P/E Forward = 50.7614
P/S = 15.0795
P/B = 30.6055
P/EG = 3.0883
Revenue TTM = 20.56b USD
EBIT TTM = 7.10b USD
EBITDA TTM = 7.50b USD
Long Term Debt = 3.72b USD (from longTermDebt, last fiscal year)
Short Term Debt = 754.0m USD (from shortTermDebt, last quarter)
Debt = 4.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.70b USD (from netDebt column, last quarter)
Enterprise Value = 308.77b USD (310.47b + Debt 4.48b - CCE 6.18b)
Interest Coverage Ratio = 41.06 (Ebit TTM 7.10b / Interest Expense TTM 172.9m)
EV/FCF = 46.35x (Enterprise Value 308.77b / FCF TTM 6.66b)
FCF Yield = 2.16% (FCF TTM 6.66b / Enterprise Value 308.77b)
FCF Margin = 32.40% (FCF TTM 6.66b / Revenue TTM 20.56b)
Net Margin = 30.22% (Net Income TTM 6.21b / Revenue TTM 20.56b)
Gross Margin = 49.80% ((Revenue TTM 20.56b - Cost of Revenue TTM 10.32b) / Revenue TTM)
Gross Margin QoQ = 49.60% (prev 50.43%)
Tobins Q-Ratio = 14.43 (Enterprise Value 308.77b / Total Assets 21.39b)
Interest Expense / Debt = 0.95% (Interest Expense 42.5m / Debt 4.48b)
Taxrate = 13.21% (242.6m / 1.84b)
NOPAT = 6.16b (EBIT 7.10b * (1 - 13.21%))
Current Ratio = 2.26 (Total Current Assets 14.02b / Total Current Liabilities 6.21b)
Debt / Equity = 0.44 (Debt 4.48b / totalStockholderEquity, last quarter 10.15b)
Debt / EBITDA = -0.23 (Net Debt -1.70b / EBITDA 7.50b)
Debt / FCF = -0.25 (Net Debt -1.70b / FCF TTM 6.66b)
Total Stockholder Equity = 9.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 30.14% (Net Income 6.21b / Total Assets 21.39b)
RoE = 62.59% (Net Income TTM 6.21b / Total Stockholder Equity 9.93b)
RoCE = 52.02% (EBIT 7.10b / Capital Employed (Equity 9.93b + L.T.Debt 3.72b))
RoIC = 42.99% (NOPAT 6.16b / Invested Capital 14.33b)
WACC = 12.94% (E(310.47b)/V(314.95b) * Re(13.12%) + D(4.48b)/V(314.95b) * Rd(0.95%) * (1-Tc(0.13)))
Discount Rate = 13.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.17%
[DCF Debug] Terminal Value 65.02% ; FCFF base≈5.74b ; Y1≈6.61b ; Y5≈9.29b
Fair Price DCF = 65.03 (EV 79.66b - Net Debt -1.70b = Equity 81.36b / Shares 1.25b; r=12.94% [WACC]; 5y FCF grow 17.85% → 2.90% )
EPS Correlation: -82.67 | EPS CAGR: -37.50% | SUE: 0.48 | # QB: 0
Revenue Correlation: 32.55 | Revenue CAGR: 7.60% | SUE: 2.67 | # QB: 6
EPS next Quarter (2026-03-31): EPS=1.33 | Chg30d=+0.143 | Revisions Net=+9 | Analysts=24
EPS current Year (2026-06-30): EPS=5.21 | Chg30d=+0.369 | Revisions Net=+13 | Growth EPS=+25.9% | Growth Revenue=+20.2%
EPS next Year (2027-06-30): EPS=6.58 | Chg30d=+0.943 | Revisions Net=+14 | Growth EPS=+26.2% | Growth Revenue=+20.8%
P/E Forward = 50.7614
P/S = 15.0795
P/B = 30.6055
P/EG = 3.0883
Revenue TTM = 20.56b USD
EBIT TTM = 7.10b USD
EBITDA TTM = 7.50b USD
Long Term Debt = 3.72b USD (from longTermDebt, last fiscal year)
Short Term Debt = 754.0m USD (from shortTermDebt, last quarter)
Debt = 4.48b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.70b USD (from netDebt column, last quarter)
Enterprise Value = 308.77b USD (310.47b + Debt 4.48b - CCE 6.18b)
Interest Coverage Ratio = 41.06 (Ebit TTM 7.10b / Interest Expense TTM 172.9m)
EV/FCF = 46.35x (Enterprise Value 308.77b / FCF TTM 6.66b)
FCF Yield = 2.16% (FCF TTM 6.66b / Enterprise Value 308.77b)
FCF Margin = 32.40% (FCF TTM 6.66b / Revenue TTM 20.56b)
Net Margin = 30.22% (Net Income TTM 6.21b / Revenue TTM 20.56b)
Gross Margin = 49.80% ((Revenue TTM 20.56b - Cost of Revenue TTM 10.32b) / Revenue TTM)
Gross Margin QoQ = 49.60% (prev 50.43%)
Tobins Q-Ratio = 14.43 (Enterprise Value 308.77b / Total Assets 21.39b)
Interest Expense / Debt = 0.95% (Interest Expense 42.5m / Debt 4.48b)
Taxrate = 13.21% (242.6m / 1.84b)
NOPAT = 6.16b (EBIT 7.10b * (1 - 13.21%))
Current Ratio = 2.26 (Total Current Assets 14.02b / Total Current Liabilities 6.21b)
Debt / Equity = 0.44 (Debt 4.48b / totalStockholderEquity, last quarter 10.15b)
Debt / EBITDA = -0.23 (Net Debt -1.70b / EBITDA 7.50b)
Debt / FCF = -0.25 (Net Debt -1.70b / FCF TTM 6.66b)
Total Stockholder Equity = 9.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 30.14% (Net Income 6.21b / Total Assets 21.39b)
RoE = 62.59% (Net Income TTM 6.21b / Total Stockholder Equity 9.93b)
RoCE = 52.02% (EBIT 7.10b / Capital Employed (Equity 9.93b + L.T.Debt 3.72b))
RoIC = 42.99% (NOPAT 6.16b / Invested Capital 14.33b)
WACC = 12.94% (E(310.47b)/V(314.95b) * Re(13.12%) + D(4.48b)/V(314.95b) * Rd(0.95%) * (1-Tc(0.13)))
Discount Rate = 13.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.17%
[DCF Debug] Terminal Value 65.02% ; FCFF base≈5.74b ; Y1≈6.61b ; Y5≈9.29b
Fair Price DCF = 65.03 (EV 79.66b - Net Debt -1.70b = Equity 81.36b / Shares 1.25b; r=12.94% [WACC]; 5y FCF grow 17.85% → 2.90% )
EPS Correlation: -82.67 | EPS CAGR: -37.50% | SUE: 0.48 | # QB: 0
Revenue Correlation: 32.55 | Revenue CAGR: 7.60% | SUE: 2.67 | # QB: 6
EPS next Quarter (2026-03-31): EPS=1.33 | Chg30d=+0.143 | Revisions Net=+9 | Analysts=24
EPS current Year (2026-06-30): EPS=5.21 | Chg30d=+0.369 | Revisions Net=+13 | Growth EPS=+25.9% | Growth Revenue=+20.2%
EPS next Year (2027-06-30): EPS=6.58 | Chg30d=+0.943 | Revisions Net=+14 | Growth EPS=+26.2% | Growth Revenue=+20.8%